Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations

BACKGROUND: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Combination therapies with first-generation EGFR-TKIs and bevacizumab have been reported to prolong progression-free survival (PFS). However, there are few data on the combination of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Ryo, Shukuya, Takehito, Imamura, Chiyo K., Tokito, Takaaki, Shimada, Naoko, Koyama, Ryo, Yamada, Kazuhiko, Ishii, Hidenobu, Azuma, Koichi, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867760/
https://www.ncbi.nlm.nih.gov/pubmed/33569303
http://dx.doi.org/10.21037/tlcr-20-824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867760/
https://www.ncbi.nlm.nih.gov/pubmed/33569303
http://dx.doi.org/10.21037/tlcr-20-824

Ejemplares similares